Literature DB >> 24240014

Delivery of basic fibroblast growth factors from heparinized decellularized adipose tissue stimulates potent de novo adipogenesis.

Qiqi Lu1, Mingming Li2, Yu Zou2, Tong Cao3.   

Abstract

Scaffolds based on decellularized adipose tissue (DAT) are gaining popularity in adipose tissue engineering due to their high biocompatibility and adipogenic inductive property. However, previous studies involving DAT-derived scaffolds have not fully revealed their potentials for in vivo adipose tissue construction. With the aim of developing a more efficient adipose tissue engineering technique based on DAT, in this study, we investigated the in vivo adipogenic potential of a basic fibroblast growth factor (bFGF) delivery system based on heparinized DAT (Hep-DAT). To generate this system, heparins were cross-linked to mouse DATs by using 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide and N-Hydroxysuccinimide. The bFGF-binding Hep-DATs were first tested for controlled release ability in vitro and then transplanted subcutaneously. Highly vascularized adipose tissues were formed 6weeks after transplantation. Histology and gene expression analysis revealed that majority of the Hep-DAT scaffolds were infiltrated with host-derived adipose tissues that possessed similar adipogenic and inflammatory gene expression as endogenous adipose tissues. Additionally, strong de novo adipogenesis could also be induced when bFGF-binding Hep-DATs were thoroughly minced and injected subcutaneously. In conclusion, our study demonstrated that bFGF-binding Hep-DAT could be an efficient, biocompatible and injectable adipogenic system for in vivo adipose tissue engineering.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adipose tissue engineering; ECM; Growth factors; Heparin

Mesh:

Substances:

Year:  2013        PMID: 24240014     DOI: 10.1016/j.jconrel.2013.11.007

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  9 in total

1.  Advancing biomaterials of human origin for tissue engineering.

Authors:  Fa-Ming Chen; Xiaohua Liu
Journal:  Prog Polym Sci       Date:  2015-03-28       Impact factor: 29.190

Review 2.  Advances in mesenchymal stem cell-based strategies for cartilage repair and regeneration.

Authors:  Wei Seong Toh; Casper Bindzus Foldager; Ming Pei; James Hoi Po Hui
Journal:  Stem Cell Rev Rep       Date:  2014-10       Impact factor: 5.739

3.   Extracellular Matrix-Based Biomaterials and Their Influence Upon Cell Behavior.

Authors:  Madeline C Cramer; Stephen F Badylak
Journal:  Ann Biomed Eng       Date:  2019-11-18       Impact factor: 3.934

4.  VEGF heparinized-decellularized adipose tissue scaffolds enhance tissue engineering vascularization in vitro.

Authors:  Mei Song; Yu Zhou; Yi Liu
Journal:  RSC Adv       Date:  2018-10-01       Impact factor: 4.036

5.  Controlling stem cell behavior with decellularized extracellular matrix scaffolds.

Authors:  Gillie Agmon; Karen L Christman
Journal:  Curr Opin Solid State Mater Sci       Date:  2016-08       Impact factor: 11.354

Review 6.  Preparation, Characterization, and Clinical Implications of Human Decellularized Adipose Tissue Extracellular Matrix (hDAM): A Comprehensive Review.

Authors:  Derek A Banyard; Vedant Borad; Eduardo Amezcua; Garrett A Wirth; Gregory R D Evans; Alan D Widgerow
Journal:  Aesthet Surg J       Date:  2015-09-01       Impact factor: 4.283

Review 7.  Hyaluronic Acid: Redefining Its Role.

Authors:  G Abatangelo; V Vindigni; G Avruscio; L Pandis; P Brun
Journal:  Cells       Date:  2020-07-21       Impact factor: 6.600

8.  Biochemical and biomechanical comparisions of decellularized scaffolds derived from porcine subcutaneous and visceral adipose tissue.

Authors:  Maohui Lin; Jinbo Ge; Xuecen Wang; Ziqing Dong; Malcolm Xing; Feng Lu; Yunfan He
Journal:  J Tissue Eng       Date:  2019-11-14       Impact factor: 7.813

Review 9.  Current Therapeutic Strategies for Adipose Tissue Defects/Repair Using Engineered Biomaterials and Biomolecule Formulations.

Authors:  Christopher M Mahoney; Cayla Imbarlina; Cecelia C Yates; Kacey G Marra
Journal:  Front Pharmacol       Date:  2018-05-17       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.